Right panel: A selective AP‐1 inhibitor, T‐5224, binds to the DNA‐binding domain of c‐FOS and mitigates the residual activity of the MM‐specific activator complex, resulting in complete IRF4 down‐regulation to augment the anti‐MM activity of lenalidomide. This evidence concerns the gene FOS and Miyoshi myopathy.